Can Eye Drops in One Eye Affect the Other?

Eye drops placed in one eye can and often do affect the other eye. The active ingredient does not stay neatly confined to the eye you treated. Some of it drains through the tear ducts into the nose and throat, enters the bloodstream, and circulates throughout the body, including to the untreated eye. This “contralateral effect” has been documented most thoroughly with glaucoma medications, where pressure-lowering drops applied to just one eye produce a measurable pressure drop in the fellow eye as well.

How Eye Drops Escape the Treated Eye

A single eye drop is a surprisingly large dose for a tiny organ. The average drop delivers roughly 30 to 50 microliters of fluid, but the eye can only hold about 7 to 10 microliters on its surface at any moment. The excess has to go somewhere. Some spills over the eyelid onto your cheek, but a large portion drains through the puncta, the two small openings at the inner corner of each eyelid, into the nasolacrimal duct and down into the nasal cavity. The mucous membranes lining the nose and throat are rich in blood vessels and absorb drugs efficiently, delivering them straight into the general circulation without first passing through the liver. This bypass of the liver’s filtering function means that a surprisingly high fraction of the drug enters your bloodstream in its active form.¹

The concentrations of active ingredients in ophthalmic drops are typically far higher than what’s needed to treat the eye itself. Manufacturers formulate them this way because the eye’s natural defenses, including blinking, tear turnover, and the corneal barrier, block most of the drug from reaching its target tissue inside the eye. To compensate, formulations pack in a high concentration so that even a small percentage absorbed through the cornea is enough to be therapeutic. But the leftover drug, the majority of the drop, is what enters systemic circulation and can reach other parts of the body, the other eye included.

The Contralateral Pressure Effect in Glaucoma Drops

The clearest evidence that drops in one eye affect the other comes from studies of glaucoma medications, where researchers can measure the effect precisely by tracking intraocular pressure (IOP) in both eyes. When timolol, one of the most widely used beta-blocker eye drops, is applied to just one eye, IOP in the untreated fellow eye drops by about 3 mmHg within a couple of hours.² That is not a trivial number when you consider that the total pressure reduction doctors aim for in treating glaucoma is often only 5 to 8 mmHg. A five-year trial of timolol in patients with ocular hypertension confirmed a similar contralateral reduction, averaging about 2.9 mmHg in the untreated eyes.³

It is not only beta-blockers that do this. Prostaglandin analogs, the other major class of glaucoma drops, also produce a contralateral pressure reduction, though the timing is a bit different. One study found that when a prostaglandin analog was applied to one eye, the untreated eye’s pressure dropped by about 2.7 mmHg in the morning and 2.3 mmHg around midday, though the effect faded to a statistically insignificant level by the afternoon.⁴ The bigger the pressure drop in the treated eye, the bigger the drop in the fellow eye, suggesting the two are linked by systemic absorption rather than some local neural reflex.

Why Doctors Care About This Cross-Over

This contralateral effect is more than a pharmacological curiosity. It has real consequences in clinical practice. Eye doctors sometimes perform what is called a monocular therapeutic trial: they prescribe a new glaucoma medication to one eye and use the other eye as a built-in control, comparing the pressure in both eyes after a few weeks to judge whether the drug is working. If the untreated eye’s pressure also drops because of systemic absorption, the drug looks less effective than it actually is. The doctor sees a smaller difference between the two eyes and might conclude the medication is not doing much, when in reality it is doing quite a lot in the treated eye and also partly treating the untreated one.

Researchers in the Ocular Hypertension Treatment Study specifically warned about this problem, noting that the contralateral effect of beta-blockers is large enough to distort results whenever a one-eyed trial is used to evaluate a topical medication.⁵ In clinical trials, this means researchers need to account for cross-over absorption when designing studies, or they risk underestimating how well a drug actually works.

For the average patient, the practical takeaway is more straightforward. If your ophthalmologist prescribes a pressure-lowering drop for just one eye, the other eye will likely see some benefit too, though not as much as the treated one. And if you are being evaluated for how well your drops are working, your doctor should be aware of this spillover and interpret the pressure readings accordingly.

Beyond Pressure: Systemic Side Effects That Reach the Whole Body

The contralateral pressure effect is actually just one symptom of a broader phenomenon: eye drops entering your general circulation. Once in the bloodstream, the active ingredient does not just visit the other eye. It reaches the heart, the lungs, the brain, and other organs. This is why timolol eye drops, which are beta-blockers, can slow your heart rate, lower your blood pressure, and trigger bronchospasm in people with asthma. The drug is doing to your heart and lungs exactly what a beta-blocker pill would do, just in a smaller and less predictable dose.

Mydriatic drops, the ones used to dilate your pupils during an eye exam, offer another example. Drugs like phenylephrine and cyclopentolate, when given as standard-sized drops, caused significant blood pressure increases in infants in one study. When the same drugs were given as smaller microdrops, the pupil still dilated adequately but the systemic blood pressure changes disappeared.⁶ The excess volume in a standard drop was not making the pupils any bigger. It was just spilling into the bloodstream and pushing blood pressure up.

Corticosteroid eye drops present a different twist. When applied to one eye over time, they can raise intraocular pressure in the treated eye as a side effect. Whether this pressure rise consistently crosses over to the untreated eye through systemic absorption is less well documented than with beta-blockers, but the principle of systemic absorption still applies. A physician who followed over 100 patients receiving corticosteroid drops to one eye reported large and significant IOP increases in many of them, underscoring that even seemingly local treatments have systemic reach.⁷

Children Face Higher Risks

If systemic absorption matters in adults, it matters even more in children. Eye drops are not dosed by body weight the way oral medications are. A standard drop of timolol delivers roughly the same amount of drug whether you weigh 200 pounds or 20 pounds. In a small child, that fixed dose translates to a much higher concentration per kilogram of body weight.

On top of that, infants and young children metabolize drugs less efficiently. Their livers are still developing, and the blood-brain barrier, which protects the brain from circulating chemicals, is not yet fully mature.⁸ This combination of higher relative dosing and less effective drug clearance puts children at significantly greater risk for systemic side effects from eye drops.¹ There have been case reports of serious cardiovascular and respiratory events in infants given routine ophthalmic medications. For pediatric patients, the question is not just whether drops reach the other eye but whether they reach the heart, lungs, and central nervous system at doses high enough to cause trouble.

Simple Techniques to Limit Spillover

The good news is that a straightforward physical technique can substantially reduce how much drug reaches the bloodstream. Nasolacrimal occlusion, which simply means pressing a finger against the inner corner of the eye near the nose for a minute or two after instilling a drop, physically blocks the tear drainage pathway. This keeps more of the drug on the eye’s surface, where it can be absorbed locally, and prevents it from draining into the nose and entering the bloodstream.

Studies confirm that nasolacrimal occlusion reduces systemic absorption, but they also consistently find that most people do it poorly or not at all.⁹ Many patients have never been taught the technique, and even those who know about it often skip it because holding a finger to your eye for a full minute feels tedious. Some ophthalmologists now teach an alternative called the “tissue press method,” which uses a folded tissue pressed against the inner corner of the eye. It is easier for patients to do consistently and appears to achieve a similar reduction in nasolacrimal drainage.

Other practical steps can also help:

Close your eyes gently: After the drop goes in, close your eyes without squeezing. Squeezing pumps tears (and the drug) into the drainage ducts faster.
Blot excess fluid: Dab away any drop that spills onto your cheek or eyelid. That excess would otherwise be absorbed through the skin or drain into the nose.
Wait between different drops: If you use more than one type of eye drop, waiting five minutes between them gives the first drop time to absorb into the eye rather than being washed away (and drained into your system) by the second drop.

For children, the smaller drop volumes that researchers have tested show promise. As the infant study with mydriatics demonstrated, cutting the drop size can preserve the desired local effect while eliminating unwanted systemic consequences. Some clinicians already use this approach in pediatric settings, though standard commercial dropper bottles are not designed to deliver microdrops, which makes it tricky in everyday practice.

When Cross-Over Effects Might Be Helpful

Most of the discussion around the contralateral effect frames it as a problem, something that confuses clinical trials and exposes the body to unintended drug exposure. But there is a flip side. If you have glaucoma or elevated pressure in both eyes and you are prescribed drops for just one eye (as sometimes happens in early-stage treatment or in a trial period), the untreated eye is getting some protection for free. That 2 to 3 mmHg of pressure reduction in the untreated eye might not be the full treatment dose, but it is not nothing.

Research on beta-blocker eye drops has also shown effects on ocular blood flow. In one study, patients who added a beta-blocker eye drop to their regimen saw increased blood flow to the choroid, the vascular layer behind the retina, and this was associated with a slower rate of visual field loss from glaucoma.¹⁰ Because the drug reaches both eyes systemically, this blood flow benefit could plausibly extend to the fellow eye as well, though that specific crossover has not been isolated in controlled studies.

The broader lesson is that the contralateral effect is neither purely good nor purely bad. It depends on the situation. For a patient with bilateral glaucoma, some spillover to the other eye might be modestly helpful. For a patient whose doctor is trying to carefully assess the drug’s efficacy in one eye versus the other, that same spillover muddies the picture.

Drops That Likely Stay Local

Not every type of eye drop produces a meaningful contralateral effect. The cross-over is most pronounced with drugs designed to be potent at low concentrations and that are easily absorbed through mucous membranes. Timolol is the classic example: it is lipophilic, meaning it dissolves readily in fats, and it crosses biological membranes easily. That is exactly what makes it effective on the eye’s surface and also what allows it to slip into the bloodstream so efficiently.

Artificial tears and lubricating drops, by contrast, are mostly saline or hyaluronic acid-based solutions. They do not contain a pharmacologically active ingredient that would produce effects elsewhere in the body. If you put artificial tears in one eye, the other eye is not going to get lubricated. The same goes for most over-the-counter allergy drops containing antihistamines like ketotifen: while some systemic absorption occurs, the doses are low enough and the drug’s systemic effects mild enough that a contralateral ocular effect is not a real concern in practice.

Where patients should be most aware of cross-over effects is with prescription medications, particularly beta-blockers, prostaglandin analogs, cholinergic agents, and corticosteroids. These are potent drugs, used at high local concentrations, and they produce measurable systemic effects. If you are on one of these medications and notice something unusual, whether it is a change in heart rate, breathing difficulty, or an unexplained change in the untreated eye, the drops are a plausible explanation worth mentioning to your doctor.

The Timing Factor

One detail that often gets overlooked is that the contralateral effect is not constant throughout the day. The prostaglandin analog study showed this clearly: the pressure reduction in the untreated eye was strongest in the morning hours and essentially gone by late afternoon.⁴ This pattern makes sense pharmacokinetically. After a drop is absorbed into the bloodstream, the drug’s concentration peaks and then gradually falls as the body metabolizes it. The fellow eye sees the highest effect near peak blood levels and a diminishing effect afterward.

For patients and clinicians, this timing wrinkle matters when scheduling pressure checks. If your doctor measures your eye pressure late in the afternoon, the contralateral spillover from a morning dose might be negligible, giving a more accurate picture of the untreated eye’s true baseline. If the check happens mid-morning, the cross-over effect could still be in play, making the untreated eye look better than it really is on its own. Doctors who understand this timing can schedule measurements accordingly and get a truer sense of what each eye is doing independently.

The same logic applies to systemic side effects. If timolol eye drops slow your heart rate, the effect will peak roughly 30 minutes to two hours after instillation and taper from there. A patient who feels lightheaded or short of breath within that window after using their drops should take it seriously, even though the drug was “just” an eye drop. By the time several hours have passed, circulating drug levels drop considerably, and the systemic effects fade, which is why some patients notice symptoms only in the period right after using their drops and then feel fine for the rest of the day.